Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia

Inclusion Criteria: * Male or female patients 19 ≤ age \< 65 years * At least 1 year of schizophrenia diagnosed according to DSM-5 criteria(295.90) * At least 1 psychotic episode within 1 year * Current psychotic episode(acute exacerbation of schizophrenia) within 2 weeks * 80 ≤ PANSS total score ≤ 120 * Rating of at least 4(moderate) on at least 2 of the following 4 PANSS positive symptoms * CGI-S score ≥ 4 * Patients who can be hospitalized during the screening period and at least 3 weeks of the initial double-blind treatment phase Exclusion Criteria: 1. Psychiatric Criteria * Medical history except schizophrenia specified in protocol * First-episode psychosis * Treatment-resistant schizophrenia within 2 years * Positive result from the blood alcohol concentration(BAC) test or the urine drug screen(UDS) * Have suicide risk 2. Treatment-related Criteria * Electroconvulsive therapy(ECT) within 12 weeks or Previous lack of response to ECT * Concomitant treatment with 3 or more antipsychotics within 12 weeks * Treatment with flunitrazepam or LAI antipsychotics less than 1 cycle or clozapine within 24 weeks * Treatment with CYP3A4 inducers or potent CYP3A4 inhibitors * Treatment with amiodarone or systemic corticosteroids for ≥ 12 weeks within 1 year * Required prohibited concomitant medication during the study period * Prior participation in any clinical trials of Cariprazine 3. Other * Ophthalmic medical findings or related history(ex. uncontrolled diabetes or hypertension) * Abnormal laboratory findings specified in protocol * Not suitable for any other reason, as judged by the investigator